In Work Package 6, biomarker development and measurement will provide 4 key objectives:
- Evaluation of biomarkers in an FDA approved lab under GLP/CLIA conditions enabling FDA submission and commercialisation.
- Selection of biomarkers from Omics data, and development of simple in vitro diagnostic tools for worldwide use.
- Validation of selected biomarkers in clinical trials compared to gold standard markers.
- Selection of a biomarker, generating the FDA package as part of commercialisation efforts. This is crucial to provide a selected, developed and produced marker to laboratories worldwide.